APLA Physiology
Antiphospholipid syndrome (APS) is a thrombo-inflammatory autoimmune disease driven by antiphospholipid antibodies (aPL) that recognize phospholipid surfaces and phospholipid-binding proteins, inducing thrombosis, pregnancy morbidity, and other inflammatory manifestations through complex interactions with the coagulation cascade and cellular targets 1.
Core Pathophysiological Mechanisms
Antibody-Mediated Activation
The pathogenic aPL—particularly anti-β2-glycoprotein I (anti-β2GPI) antibodies, especially those targeting Domain I—initiate a cascade of prothrombotic events. These antibodies don't simply interfere with coagulation tests; they actively transform the vascular environment into a prothrombotic state 2, 3.
The key mechanism involves aPL binding to phospholipid-binding proteins (primarily β2GPI) on cell surfaces, triggering cellular activation rather than directly blocking coagulation factors 3, 4. This is fundamentally different from typical anticoagulants—hence the paradoxical name "lupus anticoagulant" for antibodies that actually cause thrombosis.
Platelet Hyperactivation: The Central Driver
Recent evidence reveals that platelets undergo a graded, sustained activation that integrates immune signaling with coagulation 2, 5. This isn't simple platelet aggregation:
- Tissue factor-positive (TF+) platelets emerge as the critical pathogenic phenotype, creating a procoagulant surface even without full adhesive activation
- Anti-β2GPI antibodies induce this selective TF+ phenotype through ApoER2-dependent signaling in circulating platelets (not bone marrow programming) 2
- This creates a "two-hit" model: aPL prime platelets to express tissue factor, then inflammatory mediators (particularly IL-6) amplify this into full thromboinflammatory activation with P-selectin expression, integrin activation, and phosphatidylserine exposure 2
The platelet dysfunction persists despite anticoagulation, explaining residual thrombotic risk in treated patients 2, 5.
Cellular Targets Beyond Platelets
aPL affect multiple cell types simultaneously 3:
- Endothelial cells: Shift to a prothrombotic, proinflammatory phenotype with increased tissue factor expression and adhesion molecule upregulation
- Monocytes: Form platelet-leukocyte heteroaggregates that amplify tissue factor expression
- Trophoblasts: In pregnancy, aPL cause abnormal cellular proliferation and differentiation, leading to placental injury and pregnancy loss 3
The Inflammation Requirement
Inflammation serves as the necessary bridge between the procoagulant phenotype and actual thrombus formation 3. aPL alone create a primed, prothrombotic state, but clinical thrombosis typically requires a "second hit"—infection, surgery, trauma, or other inflammatory stimulus. This explains why not all aPL-positive individuals develop thrombosis and why events often cluster around inflammatory triggers.
Antibody Heterogeneity and Pathogenicity
Not all aPL are equally pathogenic 4:
Three Major Types
Cofactor-independent aPL: Bind directly to anionic phospholipids (e.g., cardiolipin) without protein cofactors—historically considered non-pathogenic and infection-associated, though this view is now challenged 4
Cofactor-dependent aPL: Require protein cofactors (β2GPI, prothrombin) to bind phospholipids
Protein-directed aPL: Bind directly to cofactor proteins without requiring phospholipids—these are the most pathogenic, particularly anti-β2GPI Domain I antibodies 6, 4
Risk Stratification by Antibody Profile
Triple-positive patients (lupus anticoagulant + anticardiolipin + anti-β2GPI of the same isotype) show the strongest association with thrombotic and obstetric APS and highest recurrence risk 6. This reflects:
- Greater antibody diversity targeting multiple epitopes
- Higher likelihood of pathogenic Domain I-specific antibodies
- More robust cellular activation across multiple pathways
Double-positive patients (typically LA-negative) carry intermediate risk, while single-positive patients have the lowest risk—except that LA positivity alone, particularly in obstetric APS and arterial thrombosis, remains a strong independent predictor 6.
Dysregulated Platelet Checkpoints
Omics profiling reveals chronically primed platelets with dysregulated inhibitory mechanisms 2:
- Impaired CD73-adenosine-cAMP axis (normally suppresses activation)
- Enhanced ADP/P2Y12 signaling
- Membrane remodeling favoring procoagulant differentiation
This creates a baseline prothrombotic state that conventional coagulation biomarkers fail to capture, explaining why standard anticoagulation monitoring doesn't predict thrombotic risk in APS 2.
Clinical Implications of Pathophysiology
The mechanistic understanding reveals why:
- Anticoagulation alone may be insufficient: It addresses thrombin generation but not the upstream platelet and inflammatory activation
- Aspirin shows benefit in some patients: It attenuates both adhesive and TF-dependent procoagulant programs 2
- Hydroxychloroquine has selective effects: Modulates classical activation markers but not platelet-associated tissue factor 2
- Inflammatory triggers precipitate events: The primed state requires amplification to cause clinical thrombosis
This pathophysiology supports emerging precision medicine approaches targeting TF+ platelets specifically, rather than broad anticoagulation alone 2.